New myelofibrosis drug tested in patients with liver issues

NCT ID NCT07480824

Recruiting now Disease control Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study is testing a drug called TQ05105 in people with mild or moderate liver impairment and healthy volunteers. The goal is to see how the liver affects the drug's levels in the body and check for safety. 24 participants will receive a single dose and be monitored closely.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TQ05105 (a JAK/ROCK inhibitor drug)
What this could lead to: If successful, this study could help determine safe dosing of TQ05105 for people with liver problems who have myelofibrosis.
What could go wrong: This is a very early Phase 1 trial with only 24 participants, so results may not apply broadly. The drug may still cause side effects or not work as expected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myelofibrosis primary myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELOFIBROSIS

Contacts and locations

Locations

The First Affiliated Hospital of Henan University of Science & Technology
RECRUITING

Luoyang, Henan, 471000, China
The First Affiliated Hospital of Shandong First Medical University (Qianfoshan Hospital)
NOT_YET_RECRUITING

Jinan, Shandong, 250000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.